Stratification of patients with KRAS-mutated advanced non-small cell lung cancer: improving prognostics

Yuda Zhang,Fanxu Zeng,Shixuan Peng,Yangqian Chen,Wenjuan Jiang,Zhan Wang,Li Deng,Zhe Huang,Haoyue Qin,Huan Yan,Xing Zhang,Lin Zhang,Nong Yang,Qian Gong,Liang Zeng,Yongchang Zhang

DOI: https://doi.org/10.1080/17476348.2023.2265810

2023-10-05

Expert Review of Respiratory Medicine

Abstract:Introduction KRAS is the most frequently mutated oncogene in cancer and encodes a key signaling protein in tumors. Due to its high affinity for GTP and the lack of a large binding pocket that allosteric inhibitors can occupy, KRAS has long been considered 'non-druggable.' Finding effective treatment measures for patients with KRAS mutations is our top priority.

respiratory system